<DOC>
	<DOCNO>NCT02234570</DOCNO>
	<brief_summary>The objective Phase I study evaluate safety tolerance increase single oral dos oxfendazole healthy volunteers.The secondary objective assess pharmacokinetic profile oxfendazole ass metabolism oxfendazole . The description agent use single oral dose aqueous suspension oxfendazole , benzimidazole carbamate antiparasitic drug . Each new cohort dose two week safety data precede group review . If clinically significant AE observe , event drug-related safety monitoring committee convene determine whether study continue .</brief_summary>
	<brief_title>Phase I Trial Evaluating Safety Pharmacokinetics Oxfendazole</brief_title>
	<detailed_description>This Phase I study randomize , double-blind , placebo-controlled evaluation safety pharmacokinetics escalate single oral dos oxfendazole ( 0.5 60 mg/kg ) healthy volunteer . Up 70 healthy male female ( non-chldbearing potential ) , age 18-45 volunteer recruit one site participate study . The study duration approximately 18 month subject participation 2 week . The primary objective ass safety tolerability oxfendazole healthy adult . The secondary objective assess pharmacokinetic profile oxfendazole ass metabolism oxfendazole . Two sentinel subject receive study product ( 1 drug/1 placebo ) group monitor 48 hour adverse event prior complete enrollment remain 8 subject group .</detailed_description>
	<mesh_term>Neurocysticercosis</mesh_term>
	<mesh_term>Cysticercosis</mesh_term>
	<mesh_term>Taeniasis</mesh_term>
	<mesh_term>Oxfendazole</mesh_term>
	<criteria>1 . Males females nonchildbearing potential age 18 45 year , inclusive . * *Surgically sterile via tubal ligation , bilateral oophorectomy hysterectomy postmenopausal &gt; /=1 year confirm LH FSH level . 2 . In good health , judge investigator determine vital signs* Temperature &lt; 38 degree Celsius , heart rate &lt; /=100 bpm &gt; 50 bpm , systolic blood pressure &lt; /= 140 mmHg &gt; 89 mmHg , diastolic blood pressure &lt; /=90 mmHg &gt; /= 60 mm Hg , medical history target physical examination . BMI &gt; /=18 &lt; /= 35 . Athletically trained subject pulse &gt; /= 45 may enrol discretion principal investigator designate licensed clinical investigator . 3 . Acceptable screen laboratories* *Hemoglobin , white blood cell ( WBC ) count , neutrophil , eosinophil platelet count within normal range . AST &lt; 44 ALT &lt; 44 total bilirubin , creatinine must equal upper limit normal ( eosinophil count , AST , ALT , creatinine , total bilirubin value normal range acceptable ) . Random blood glucose must &lt; 140 . Urine dipstick testing must negative glucose negative trace protein . The following serology test must negative : HIV 1/2 antibody , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibody . HIV hepatitis C viral load PCR testing may perform individual suspect indeterminate antibody test . 4 . Male participant must willing ensure use condom spermicides 4 month study drug administration . 5 . Provide write informed consent initiation study procedure . 6 . Willing available studyrequired procedure , visit duration study . 7 . Able provide home phone number , name , address , and/or email person willing assist make contact followup phase study . 1 . History reside 6 month region endemic cysticercosis determine principal investigator designate study physician . 2 . Breastfeeding female . 3 . Body temperature &gt; /=100.4 degree Fahrenheit ( &gt; /=38.0 degrees Celsius ) acute illness within 3 day administration study drug ( subject may reschedule ) . 4 . Chronic acute medical disorder* *Disorders cardiac , pulmonary , liver , kidney , neurologic , gastrointestinal system , opinion investigator participation study create additional risk subject , validity study . 5 . Use chronic systemic medications* *Intermittent use counter medication acetaminophen , ibuprofen , cold sinus medication permit enrollment ( please see section 5.6 instruction medication use study ) .Topical medication , nasal steroid permit throughout study . Use prescription medication use less per week average permit enrollment ( see section 5.6 instruction medication use study ) . If subject take short term prescription medication within past 30 day ( e.g . antibiotic ) , postpone enrollment 30 day elapse since last dose 6 . Has history sensitivity relate benzimidazole compound ( e.g. , albendazole , mebendazole ) . 7 . A diagnosis schizophrenia , bipolar disease , history hospitalization psychiatric condition previous suicide attempt . 8 . A history treatment psychiatric disorder past 3 year . * *Past treatment ADHD exclude participant enrollment long medication discontinue minimum 3 month symptoms well control . 9 . Received experimental agent* within 1 month administration study drug expect receive experimental agent 15day study period . *Vaccine , drug , biologic , device , blood product , medication . 10 . Any condition would , opinion investigator , place unacceptable risk injury , render unable meet requirement protocol , may interfere successful completion study . 11 . A history alcohol consumption* illicit drug use† , history substance abuse # . Individuals must agree abstain drug alcohol use 48 hour prior enrollment day 15 . *Greater 7 alcoholic drink per week . †Other occasional marijuana use ( less per week past 60 day acceptable ) . # Alcohol illicit drug within past 3 year . 12 . History chronic tobacco use past 60 day . * *A history occasional tobacco use ( less 1 pack per week average ) acceptable . Individuals counsel abstain use tobacco marijuana screen day 15 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>neurocysticercosis</keyword>
	<keyword>pork tapeworm</keyword>
	<keyword>Taenia solium</keyword>
</DOC>